Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

NCT03515837 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

492

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: pembrolizumab
DRUG: pemetrexed
DRUG: carboplatin
DRUG: cisplatin
DRUG: saline solution

Sponsor

Merck Sharp & Dohme LLC